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Abstract
The choroid plexus (CP) provides a barrier to entry of toxic mole-
cules from the blood into the brain and transports vital molecules
into the cerebrospinal fluid. While a great deal is known about CP
physiology, relatively little is known about its immunology. Here,
we show immunohistochemical data that help define the role of the
CP in innate and adaptive humoral immunity. The results show that
complement, in the form of C1q, C3d, C9, or C9neo, is preferentially
deposited in stromal concretions. In contrast, immunoglobulin (Ig)
G (IgG) and IgA are more often found in CP epithelial cells, and
IgM is found in either locale. C4d, IgD, and IgE are rarely, if ever,
seen in the CP. In multiple sclerosis CP, basement membrane C9 or
stromal IgA patterns were common but were not specific for the dis-
ease. These findings indicate that the CP may orchestrate the clear-
ance of complement, particularly by deposition in its concretions,
IgA and IgG preferentially via its epithelium, and IgM by either
mechanism.
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INTRODUCTION
The choroid plexus (CP) is a frond-like structure proj-
ecting into the cerebrospinal fluid (CSF) of the ventricular
system of the brain. It is comprised of a simple cuboidal epi-
thelium resting on a basement membrane (BM) overlying a
fibrovascular stroma (Figs. 1, 2A–C) (1). Patrolling the ven-
tricular surface of the CP epithelium are epiplexus cells
(Kolmer cells), which are thought to be macrophages (2). Stro-
mal blood vessels possess fenestrated endothelia (1). The CP
stroma and BM are therefore exposed to circulating molecules
(Fig. 2D), the barrier to their entry to the CSF being at the
level of CP epithelial cells. The morphologic basis for this
blood–CSF barrier is in the form of tight junctions between ad-
jacent epithelial cells (Fig. 1), in a manner similar to the
blood–brain barrier at the level of the CNS endothelium (3, 4).
The fibrous component of the stroma shows varying degrees
of collagen compaction, some focal regions being intensely
sclerotic and, in many instances, calcified (Fig. 2C). Up to
now, these sclerotic structures (which we refer to as “concre-
tions”) have not been emphasized. These structures are hyali-
nized and somewhat irregular in shape and differ from psam-
moma bodies, which are well-delineated spherical, somewhat
laminated, often larger structures that tend to be clustered and
presumably originate within the remnants of the leptomenin-
geal embryologic contribution to the CP.
The best-known role of the CP is the production of CSF
(5) (Fig. 1), which provides buoyancy for the brain in the rigid
skull and for the spinal cord in the vertebral column. The CSF
also serves as a strategically placed intermediary for the pas-
sage of molecules into and out of the CNS (Fig. 1). Thus, uti-
lizing a myriad of molecular transporters, it transports specific
molecules from the blood into the CSF, many of these having
trophic effects on the CNS both during development and in
adult life (6–8) (Fig. 1). The CP also has a system of efflux
transporters that remove waste products and toxic substances
from the CSF (9) (Fig. 1).
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FIGURE 1. Schematic diagram of directionality of ions and molecules in the choroid plexus (CP). Three CP epithelial cells (cytoplasm in
purple, nuclei in blue, numbered by nucleus), joined by tight junctions (small black rectangles), rest on a basement membrane (red)
overlying the stroma. In the stroma, there are corpora amylacea, a blood vessel, and a concretion. Cell 1 illustrates ionic channels
(rectangles with directional arrows) and pumps (small circles with directional arrows), color coded to match their respective names.
They are positioned in the apical or basolateral cell membrane as indicated. Their combined effect is responsible for cerebrospinal fluid
(CSF) production, creating an osmotic gradient that causes a net movement of water from the extracellular space of the stroma,
through the epithelial cell cytoplasm, and into the ventricle via AQP1 water channels. Carbonic anhydrase (not shown) is the major
enzyme responsible for the generation of Hþand HCO"3 . For a review of ionic channels and pumps and their role in CSF formation, see
Damkier et al (5). Cell 2 shows the transport systems for larger molecules. These comprise the efflux transporters that transport
substances (particularly lipid compounds) out of the CSF, inward transporters that transport relatively small molecules into the CSF,
bidirectional transporters that transport molecules in either direction, and protein transporters that transport individual specific proteins
into the CSF. Some substances are transported in vesicles. For a review of transporters in the CP, see Saunders et al (7). Cell 3, its
associated basement membrane, underlying stroma, and stromal blood vessel show postulated mechanisms of handling complement
and immunoglobulin (Ig). The thin black arrows indicating directionality of movement are speculative. Our results would suggest that
complement (green dots) from serum or CSF is frequently deposited in concretions by associating with the basement membrane that is
eventually incorporated into the concretion. Our data also indicate that IgM is also deposited in concretions but may also be handled
by epithelial cells, whereas IgA and IgG are predominately handled by epithelial cells. Abbreviations: AE2, anion exchanger 2 (Cl"/
HCO"3 exchanger); AQP1, aquaporin-1 water channel; Cl, chloride ions (Cl
"); H, hydrogen ions (Hþ); HCO3, bicarbonate ion (HCO
"
3 );
K, potassium ions (Kþ); KCC3 and KCC4, Kþ–Cl" cotransporter 3 and 4; Na, sodium ions (Naþ); Na-K ATPase, Naþ-KþATPase; NBC,
Naþ–HCO"3 cotransporters; NCBE, Na
þ-dependent Cl"/HCO"3 exchanger; NHE1, Na
þ/Hþexchanger 1; NKCC1, Naþ-Kþ-2Cl"
cotransporter 1. Adapted from Figure 11 in Damkier HH, Brown PD, Praetorius J. Cerebrospinal fluid secretion by the choroid plexus.
Physiol Rev 2013:93;1847–92 and Figure 2 in Saunders NR, Daneman R, Dziegielewska KM, Liddelow SA. Transporters of the blood-
brain and blood-CSF interfaces in development and in the adult. Mol Aspects Med 2013:34;742–52.
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Over recent years, it has become increasingly evident
that the CP has a pivotal role in the cellular immunology of
the CNS (10). In contrast to many of the tenets of the long-
standing notion of immunological privilege of the CNS, it is
now widely accepted that T lymphocytes regularly track
through the CNS as part of their immune-surveillance mandate
(11). These are predominately central memory T cells (12),
which are confined to the CSF and do not enter the paren-
chyma. Once the immune response is activated after antigen
presentation to T cells within the subarachnoid space, the re-
cruitment of effector T cells to the endothelium, and thence
the perivascular space and their entry into the CNS paren-
chyma through the previously impenetrable glia limitans, can
occur (13). T cells may enter the CP stroma via P-selectin and
intercellular adhesion molecule-1, which are expressed on
stromal venular endothelia (14). The entry portal from the
stroma through the CNS barriers for the initial wave of Th17
cells (currently regarded as an important T-cell subset in the
FIGURE 2. Macroscopic and microscopic features of the choroid plexus (CP). (A) The CP is a frond-like structure (white arrow),
shown here in the lateral ventricle. (B) Micrograph of hematoxylin and eosin (H&E) stain shows the CP is a papillary structure
comprised of a cuboidal epithelium and a fibrovascular stroma. (C) Under higher magnification, the cuboidal structure of the
epithelial cells, as well as the fibrous tissue and vasculature of the stroma (S), is evident. In the stroma, there are several
concretions comprised of dense fibrous tissue (black arrowheads), some of which show calcification, varying from early (small
black arrow, and shown at higher magnification in inset) to advanced (large black arrows). (D) The normal permeability of CP
blood vessels is evident by the extravasation of high molecular weight molecules, in this case fibrinogen (green), into the stroma.
The basement membrane is stained for collagen IV (red); epithelial cells are stained for transthyretin (purple). Cell nuclei are
stained with 40,6-diamidino-2-phenylindole (DAPI) (blue). (E) Confocal immunofluorescence demonstrates 3 concretions
(asterisks) as irregularly blue-staining regions when the DAPI (blue) brightness is enhanced. The concretions show the
incorporation of basement membrane material (red, stained for collagen IV), which normally is located just beneath the
epithelium (red arrows). The middle concretion is associated with a defect (between the white arrows) in the subepithelial
basement membrane, which also shows thickening adjacent to the right edge of the defect. The concretion on the right shows
thickening and duplication of the overlying subepithelial basement membrane. The basement membrane is also normally seen in
the walls of stromal blood vessels (in cross-section in the lower middle and in longitudinal section in the lower right of the panel).
Scale bars: white¼20 mm; blue¼50 mm; black¼200 mm.
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mediation of autoimmune demyelination) is the CP epithelium;
this may apply to other T-cell subtypes, including T regulatory
cells (15, 16). The migration is thought to be mediated by the
interaction of the cytokine receptor CCR6 on T cells with its li-
gand CCL20 on CP epithelial cells. Other receptor ligand inter-
actions, such as those involving epithelial V-like antigen (17),
have also been proposed as mechanisms for entry of T cells
across the CP epithelium. It has also been suggested that, in
addition to the entrance of inflammatory cells and the well-
known negative effects of inflammation in the CNS, some T
cells and macrophages with trophic or positive effects on the
CNS may also enter via the CP (18, 19). However, a shift of
T cells in the CP epithelium to a Th2 phenotype in senes-
cence is associated with cognitive decline mediated by the
chemokine CCL11 (20). In addition to these local phenom-
ena, it has also been shown that CP genes respond to acute
(21) and chronic (22) inflammatory events occurring outside
the CNS, and this may be the explanation for the effect of
systemic inflammation on the manifestations of neurodegener-
ative disorders (21, 22). Furthermore, the CP is responsive to T
regulatory cells, and this may also be important in the regula-
tion of clearance of amyloid-b by inflammatory cells in experi-
mental Alzheimer disease (23). Thus, there is ample evidence
that the CP has a key role in CNS T-cell trafficking, with resul-
tant negative and positive influences on the CNS.
While most of the findings described above are from
studies in experimental animals, there have been only a few
that examined cellular immunity in the human CP. A study of
the CP in multiple sclerosis (MS) showed upregulation of
Class II MHC on macrophages in the stroma and epithelium,
similar to encephalitis, and CD68-negative cells in the stroma
thought to be dendritic cells (24). Scattered T cells, in relation
to CP vessels (somewhat fewer than in cases of encephalitis),
were evident in MS, whereas none were noted in noninflam-
matory controls. The findings were consistent with the entry
of inflammatory cells though the CP in MS patients and
were present even in the chronic progressive stages of the
disease (24).
Complement, which is part of the innate immune sys-
tem, provides one of the first defenses against microorganisms
and mediates the elimination of apoptotic or degenerating cells
(25); it also interacts with the adaptive immune response (26),
where, among other functions, it participates in the recruit-
ment and activation of lymphocytes and neutrophils (26, 27).
Complement comprises a cascade of interacting components
that generates proinflammatory triggers culminating in forma-
tion of the cytolytic membrane attack complex (MAC).
In the human CP, complement localization has been
described in schistosomiasis (28), cirrhosis (29), Alzheimer
disease (30), hypertension (31), and on apoptotic CP epithe-
lial cells in diabetic ketoacidosis (32). Complement receptor
(CR) 1 mRNA has been detected in CP epithelial cells (33),
and CR3 induction in epiplexus cells has been detected after
experimental high-altitude exposure (34). Complement regu-
lators membrane cofactor protein (CD46) (33, 35), decay
accelerating factor (CD55), and CD59 (33) have also been
documented in CP epithelia. There is upregulation of these
complement regulators by CP epithelial cells in bacterial
meningitis (36).
In experimental animals, complement deposition has
been detected in the CP in mesangiocapillary glomerulone-
phritis in lambs (37), spontaneous immune complex disease in
rats (38), experimental autoimmune encephalomyelitis (EAE)
in guinea pigs (39, 40), serum sickness in mice and rats (41,
42), and experimental trypanosomiasis in mice (43).
Interestingly, the gene for the receptor for C5a is consti-
tutively expressed on neurons in the mouse brain (44).
Moreover, in the presence of systemically circulating lipo-
polysaccharide endotoxin, the genes for the receptor for C3a,
as well as C3 and C5, are upregulated in regions without a
blood–brain barrier, such as the CP (44). These findings in the
mouse would indicate that there is a system in the CP that is
primed for complement production in the event of systemic in-
sults such as endotoxemia. This then raises the issue of the
elimination of complement and the targets to which it may be
complexed from the CNS and how complement may be con-
trolled or inactivated to prevent bystander parenchymal dam-
age beyond that required to eliminate the offending target.
In addition to the participation of individual comple-
ment components in the complement cascade that culminates
in the MAC, certain components, particularly C5a, have a che-
motactic effect on neutrophils and, as such, contribute to the
formation of cellular inflammatory infiltrates.
In contrast to complement, the adaptive immune system,
a component of which is the humoral immune response of im-
munoglobulins synthesized by B cells and their derivatives, is
antigen specific. Immunoglobulins have also been detected in
the human CP in various conditions. These include neurologi-
cally normal individuals (45), autoimmune nephritis in Good-
pasture syndrome (46), IgA nephropathy (47), systemic lupus
erythematosus (48–51), subacute bacterial endocarditis (52),
acquired immunodeficiency syndrome (53), cirrhosis (29),
Alzheimer disease (30), and hypertension (31). Immunoglobu-
lin light chains have been detected in the psammoma bodies
and the stroma of the CP (54); the stromal depositions in the
last report appear to correspond to the concretions described in
the current study.
In experimental animals, CP immunoglobulin has been
demonstrated in normal hamsters (55), spontaneous lupus-like
syndrome in nude mice (56), mesangiocapillary glomerulone-
phritis in lambs (37), spontaneous immune complex disease
(38), subcutaneous inoculation of an antigen (horseradish per-
oxidase) (57, 58), systemic injection of antibodies to proteins
(58, 59), acute and chronic serum sickness (42, 60, 61), EAE
(39, 40), experimental malaria (62), and experimental trypano-
somiasis (43).
From the above, it is clear that immunoglobulins and
complement may be evident in the CP in many circumstances,
including conditions that are not usually considered to have an
immune or autoimmune pathogenesis. It would seem, there-
fore, that their appearance in the CP is not specific, and most
likely the CP acts as a depository for immune complexes and
complement. Until now, an extensive systematic study of the
occurrence of immunoglobulins and complement in the
human CP in a range of disorders to determine if there is any
difference in the anatomic distribution of these two arms of the
immune response has not been carried out to our knowledge.
In this study, we found that immunoglobulin and complement
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deposition in the CP is exceedingly common. In fact, in one
form or another, this was found in the CP in virtually every
case, regardless of the associated clinical circumstances.
Thus, while a great deal is known about CP physiology,
until recently, relatively little attention has been paid to its im-
munology. These studies have revealed important insights into
the involvement of the CP in immunity (63). Moreover, the
predisposition of MS plaques to be proximal to CSF pathways
raises the possibility that CP barrier or filter dysfunction have
important roles in this disorder (64). For these reasons, we
examined the immunohistochemical localization of represen-
tative components of the complement cascade and of all im-
munoglobulins in the CP in MS patients and in a variety of
neurological and nonneurological control conditions. The data
show a consistent deposition of complement in the stromal
concretions regardless of the clinical setting. On the other
hand, immunoglobulins tended to localize to epithelial cells.
These findings suggest segregation of the respective mecha-
nisms of handling products of the innate and humoral arms of
the immune system within the CP.
MATERIALS ANDMETHODS
Tissue Samples
Formalin-fixed paraffin-embedded CP samples from in-
stitutionally approved, next of kin–consented autopsies on
13MS patients (Table 1, cases 1–13), 24 other neurological
conditions (Table 1, cases 14–37), and 11 nonneurological
conditions (Table 1, cases 38–48) were initially immunohisto-
chemically stained using primary antibodies to immunoglobu-
lin (Ig) G, IgA, IgM, IgD, IgE, C1q, C3d, C4d, C9, and a
neoepitope on C9 (C9neo) specific for the terminal MAC
(Table 2). To determine whether a trend noted in this series for
IgA and C9 was consistent for MS patient samples, an addi-
tional 11 cases of MS (Table 1, cases 49–59), 19 cases of other
neurological conditions (Table 1, cases 60–78), and 5 cases of
nonneurological conditions (Table 1, cases 79–83) were also
studied for IgA, C9, and C9neo.
Immunofluorescence
Three-micrometer-thick formalin-fixed paraffin sections
on 1:10 polylysine (Sigma-Aldrich, St Louis, MO)-coated
slides were deparaffinized in xylene, dehydrated in absolute
ethanol, and washed with distilled water. Depending on the pri-
mary antibody, sections were either treated with proteinase K
for 6–9minutes or microwaved in citrate buffer (pH 6.0) for
2minutes at 90% power, 2minutes at 70% power, 6minutes at
50% power, and cooled to room temperature over 20minutes
(Table 2). To reduce autofluorescence, they were treated with
1% (weight/volume) sodium borohydride (Fisher Scientific,
Fair Lawn, NJ). They were then incubated with 5% normal
donkey serum, the same species as the secondary antibody, for
30minutes. The primary antibody (Table 2) was applied over-
night at room temperature, followed by washing in phosphate-
buffered saline with 0.5% Tween (PBS-Tween). All primary
antibodies are known to recognize the appropriate antigen in
formalin-fixed paraffin-embedded tissue. Negative controls
consisted of immunoglobulins of the same subtype in the same
dilution from the same, but unimmunized, species as the pri-
mary antibody (Table 2). Fluorescent secondary antibodies
(Invitrogen [Life Technologies]/Molecular Probes, Burlington,
ON, Canada) were applied at a dilution of 1:400 for 180min-
utes in the dark (Table 2) and then washed in PBS-Tween.
DAPI (40,6-diamidino-2-phenylindole, Invitrogen) at 1:400 di-
lution was applied for 10minutes as a nuclear counterstain, fol-
lowed by coverslipping with ProLong Gold antifade mounting
medium (Invitrogen). Slides were examined with a Leica
DM4000 B fluorescence microscope (Leica Microsystems,
Wetzlar, Germany).
Staining Analysis
The anatomical localizations of staining for each pri-
mary antibody were recorded as follows: epithelial cells (EP),
subepithelial basement membrane (BM), stippled staining of
BM (BMs), BM overlying concretion (BMc), concretion (C),
stroma (S), and stromal vasculature (V). Statistical compari-
sons between MS, other neurological conditions, and non-
neurological conditions were carried out for each primary anti-
body based on the presence of staining at locations in the
CP using a 2-tailed Fisher exact test with Bonferroni correc-
tion for 70 multiple comparisons (p< 0.0007, SPSS Statistics
17.0). Statistical comparisons between the presence of each
primary antibody in relation to every other antibody in both
the concretions and the epithelial cells were carried out using
a 2-tailed Fisher exact test with Bonferroni correction for 45
multiple comparisons (p< 0.001). Finally, the percent positiv-
ity of each antibody in the concretions versus the epithelial
cells was compared with a 2-tailed Fisher exact test with Bon-
ferroni correction for 10 multiple comparisons (p< 0.005).
Confocal Microscopy
Selected sections were stained with a multiple-labeling
procedure. This comprised one of the above primary antibod-
ies combined with an antibody to collagen IV (to highlight
basement membranes) and an antibody to transthyretin (to
highlight CP epithelium) in a cocktail, followed by a cocktail
of the appropriate secondary antibodies. The same section
preparation procedures, washes, concentrations, and time-
frame as described above for the individual antibodies were
employed. DAPI was again used as the nuclear counterstain.
Sections were imaged in a Zeiss Axio-observer Z1 spinning-
disc confocal microscope (Carl Zeiss Microscopy, Oberko-
chen, Germany). Deconvolution was carried out using a near-
est-neighbor algorithm. Images were brightened x 50 in Photo-
shop CS5.1 (Adobe Systems Inc., San Jose, CA).
RESULTS
Autofluorescence of Formalin-Fixed
Paraffin-Embedded Tissues
Strong autofluorescence of red blood cells was invari-
ably present in all sections (test sections and negative con-
trols). Supplemental Digital Content shows examples of auto-
fluorescence and test slides referenced to negative controls. In
addition, Biondi bodies (or ring bodies) (65), small thread-like
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TABLE 1. Summary of Cases for Series 1 and Series 2
Series 1: C1q, C3d, C4d, C9, C9neo, IgA, IgG, IgM, IgD, IgE Series 2: IgA, C9, C9neo
Casea Age Sex PMI Diagnosis Casea Age Sex PMI Diagnosis
1 32y F 1d MS 49 76y M ?R MS
2 40y M NK MS 50 74y F 2d MS, AD
3 57y F NK MS 51 54y F 4d MS
4 49y F NK MS 52 51y F 12h MS
5 35y M 17h MS 53 76y F 12h MS
6 79y M NK MS 54 78y M ?R MS (acute on chronic)
7 58y M 3d MS 55 55y M 3d MS
8 71y F NK MS 56 45y F ?R MS, arachnoid cysts
9 57y F NK MS 57 41y F ?R MS
10 76y M NK MS 58 67y F NK MS
11 56y F NK MS 59 33y M NK MS
12 33y F NK MS 60 41y M 2h Neuroaxonal leukodystrophy
13 51y F 1d MS 61 64y F 1d B-cell lymphoma
14 19y F NK Acute disseminated encephalomyelitis 62 61y M 2d CADASIL
15 24y F 1d Subacute sclerosing panencephalitis 63 57y M 2d Mild hydrocephalus, mild Purkinje cell loss, steatosis
16 74y F 3d Arteriolo, CAA 64 80y M 5d DLBD, tau pvent glia, pallidotomy, bilat STN stimulation
17 77y F 1d Remote spinal cord injury 65 84y F 3d AD, arteriolo, !etat cribl!e
18 81y M 3d Arteriolo, lacunes, poss AD 66 68y F 2d Cerebral atrophy NYD, MI, renal cysts
19 83y F 3d Motor neuron disease 67 33y F 2d Metastatic ca, mild anoxic encep, lymphocytic thyroiditis
20 71y M 1d Remote berry aneurysm clipping 68 50y F 1d Sarcoma, chemo, DIC, gram-neg sepsis, anoxic encep
21 70y M 4d AD 69 35y F 2d Liver transplant, systemic Herpes simplex (not CNS), CPM
22 17y F 21h Hepatic cerebral edema 70 21y M 2d Hemochromatosis, hepatic failure, ? pvent demyelin, SCO
23 79y M 2.5d Mastocytosis with encephalopathy 71 70y M 1d Poss AD, CAA, hydro, arteriolo, anoxic encep, MI, steatosis
24 61y F NK Intravascular lymphoma 72 83y F 1d Old frontal infarct, abdominal aortic aneurysm, steatosis
25 61y M 1.5d IgA nephropathy, IC-hypotension, cirrhosis 73 75y M 4d Prob AD, CAA, mild pvent WM pallor, liver fibrosis, CAD
26 64y M 3d AD 74 56y F 2d Cereb infarcts, leiomyosarcoma, hypereosinophilia
27 53y F 1d TIAs, pseudomembranous colitis 75 58y F 1d EtOH cerebellar degen, sepsis, DIC, pancreatitis, steatosis
28 74y M 4h Basilar aneurysm clipping, hepatic abscesses 76 77y F 2d Meningioma NS, subacute and old cereb infarcts, PSP
29 81y M 3d Old cereb infarcts, CAD 77 63y F 2d Anoxic encep, panhypopituitarism, hypertension
30 89y M 2d Old vertebrobasilar infarcts 78 72y M 4d Poss AD, pvent WM pallor, meningeal fibrosis, Ca lung
31 76y F 1d Old cereb infarcts, CAD, pseudomemb colitis 79 69y M 4d Hepatic failure, sclerosing peritonitis
32 54y M 5h Anoxic encephalopathy, pancreatitis 80 44y F 1d Diffuse B-cell lymphoma (not CNS), steatosis
33 71y F NK AD, CAA 81 54y F 2d Polycystic kidney and liver, portal vein thrombosis
34 62y F 2d CML, prob vasculitis, spinal cord infarct 82 48y F 1d Myocarditis
35 62y F 1d Cerebral B-cell lymphoma 83 80y M 2d Cardiac surgery, Hepatic steatosis and fibrosis
36 54y M 1d Prev medulloblast NS, old cereb infarcts
37 51y F 3d NHL, cyclosporin, rxed PRES
38 60y F 7h Metastatic breast Ca
39 59y M 3d Prob Wegener’s granulomatosis
40 56y M 3d Tacrolimus treatment, Liver transplant
41 62y M 3d HPL, T-cell Lymphoma
42 57y M 4d Aortic Aneurysm
43 32y F 1d Pancreatitis, IBS, Asthma
44 74y M 18h Hepatic Abscess, Crohn’s Disease
45 41y F 3d Endocarditis, Cirrhosis
46 71y M 3d MI, Arteriolo
47 49y F 4d Ovarian and Breast Ca
48 59y M 2d Hepatocellular Ca
AD, Alzheimer disease; Arteriolo, arteriolosclerosis; bilat, bilateral; Ca, carcinoma; CAA, cerebral amyloid angiopathy; CAD, atherosclerotic coronary artery disease; CADA-
SIL, cerebral autosomal dominant arteriopathy with subacute infarcts and leukoencephalopathy; Cbll, cerebellar; Cereb, cerebral; chemo, chemotherapy; CML, chronic myeloge-
nous leukemia; CNS, central nervous system; CPM, central pontine myelinolysis; d, day(s); degen, degeneration; demyelin, demyelination; DIC, disseminated intravascular
coagulation; DLBD, diffuse Lewy body disease; encep, encephalopathy; EtOH, alcoholic; F, female; h, hours; HPL, hemophagocytic lymphohistiocytosis; hydro, hydrocephalus;
IBS, irritable bowel syndrome; IC, intracranial; M, male; medulloblast, medulloblastoma; MI, myocardial infarct; MS, multiple sclerosis; neg, negative; NHL, non-Hodgkin’s lym-
phoma; NK, not known; NS, neurosurgery; NYD, not yet diagnosed; PMI, postmortem interval; poss, possible; PRES, posterior reversible encephalopathy syndrome; Prev, previ-
ous; Prob, probable; pseudomemb, pseudomembranous; PSP, progressive supranuclear palsy; pvent, periventricular; rx’ed, treated; SCO, Sertoli-cell-only syndrome; STN,
subthalamic nucleus; TIAs, transient ischemic attacks; WM, white matter; ?R, PMI not available, referred-in-case; y, years.
aMS: cases 1–13,49–59; other neurological conditions: cases 14–37,60–78; nonneurological conditions: cases: 38–48,79–83.
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linear, curvilinear, or spherical inclusions in CP epithelial
cells, which express amyloid and accumulate with aging, also
autofluoresce (Supplementary Data). Thus, these sources of
brilliant autofluorescence were ignored when examining the
test sections.
Concretions and the Subepithelial BM
Strands of collagen IV–positive material in addition to
its immediate subepithelial location were frequently found
deep within the concretion (Fig. 2E), particularly near its epi-
thelial pole. In proximity to the concretion, the BM staining
was often attenuated, discontinuous, thickened, or duplicated
(Figs. 2E, 3B, F–H).
Complement Deposition
For C1q, the first component in the classical comple-
ment pathway, we frequently noted positivity in the CP
stroma, in concretions (Fig. 3A), and associated with the BM,
particularly overlying concretions (Table 3). Epithelial cells
were sometimes positive (Fig. 3A; Table 3). This was associ-
ated with nearby C1q-positive ependymal cells (Fig. 3A and
inset). Stromal blood vessels were occasionally positive.
C3d was deposited in concretions and often in a diffuse
or multifocal fashion in the stroma and associated with BM
overlying concretions (Fig. 3B; Table 3). Vascular C3d stain-
ing was unusual (Table 3).
Immunofluorescence for C4d, a product of activation of
both the classical and lectin complement pathways, was usu-
ally negative, aside from occasional BM-associated deposits.
The concretions were rarely positive (Table 3).
C9 showed relatively consistent staining of concretions
(Fig. 3C, F; Table 3). C9 positivity was infrequently observed
in the stroma, but stromal vascular staining was relatively fre-
quent. In contrast to C3d, in which the BM deposits generally
tended to be uniform and located particularly over concretions,
C9 frequently showed BM positivity in an irregular stippled
pattern not necessarily associated with concretions (Fig. 3C–E;
Table 3).
Staining for C9neo, which is specific for the MAC, was
frequently detected in concretions where staining was evident
either in their center or periphery (Fig. 3G, H; Table 3). BM
staining was evident (Table 3), but was generally not as obvi-
TABLE 2. Primary Antibodies and Normal Sera
Primary Antibodies Source (and Product Code; Location) Antigen Retrieval Secondary Antibody
IgA: rabbit polyclonal IgG (1:4000) Dako (A0262); Glostrup, Denmark Microwave Alexa Fluor 488 donkey anti-rabbit IgG (HþL)
IgG: goat polyclonal IgG (1:10,000) Biogenesis Technology
(5172-2104); Poole, UK
Microwave Alexa Fluor 488 donkey anti-goat IgG (HþL)
IgM: mouse monoclonal IgG1j (1:500) Dako (M0702) Microwave Alexa Fluor 488 donkey anti-mouse IgG (HþL)
IgD: mouse monoclonal IgG1j (1:500) Dako (M0703) Microwave Alexa Fluor 488 donkey anti-mouse IgG (HþL)
IgE: mouse monoclonal IgG (1:400) Affinity Bio Reagents
(SA1-19260); Golden, CO
Microwave Alexa Fluor 488 donkey anti-mouse IgG (HþL)
C1q: rabbit polyclonal (1:20) BioGenex (AR100-5R);
San Ramon, CA
Microwave Alexa Fluor 488 donkey anti-rabbit IgG (HþL)
C3d: rabbit polyclonal (1:2000) Dako (A0063) Microwave Alexa Fluor 488 donkey anti-rabbit IgG (HþL)
C4d: mouse monoclonal IgGj (1:250) Quidel Corporation
(A213); San Diego, CA
Microwave Alexa Fluor 488 donkey anti-mouse IgG (HþL)
C9: sheep polyclonal IgG (1:800) Abcam Inc (ab53896); Cambridge, MA Microwave Alexa Fluor 488 donkey anti-sheep IgG (HþL)
C9neo: mouse monoclonal IgG1 (1:100) B. P. Morgan (Clone B7); Cardiff, UK Proteinase K Alexa Fluor 488 donkey anti-mouse IgG (HþL)
Collagen IV: mouse IgG1 (1:100) Abcam Inc (ab49213) Microwave Alexa Fluor 568 donkey anti-mouse IgG (HþL)
Collagen IV: rabbit IgG (1:500) Abcam Inc (ab6586) Microwave Alexa Fluor 568 donkey anti-rabbit IgG (HþL)
Transthyretin: sheep IgG (1:2000) Abcam Inc (ab9015) Microwave Alexa Fluor 647 donkey anti-sheep IgG (HþL)
Transthyretin: chicken polyclonal
IgY (1:400)
Abcam Inc (ab106558) Microwave Alexa Fluor 647 donkey anti-chicken IgG (HþL)
Normal Sera
Normal rabbit serum IgG fraction Dako (X0903) Microwave Alexa Fluor488 donkey anti-rabbit IgG(HþL)/
Alexa Fluor568 donkey anti-rabbit IgG (HþL)
Normal mouse serum IgG 1j Sigma-Aldrich (M9269); St Louis, MO Microwave/
proteinase K
Alexa Fluor 488 donkey anti-mouse IgG (HþL)
Normal goat serum purified IgG Sigma-Aldrich (I5256) Microwave Alexa Fluor 488 donkey anti-goat IgG (HþL)
Normal sheep serum Sigma-Aldrich (S3772) Microwave Alexa Fluor 488 donkey anti-sheep IgG(HþL)/
Alexa Fluor 647 Donkey anti-Sheep IgG (HþL)
Normal chicken serum Jackson Immuno Research Labs
(003-000-120); West Grove, PA
Microwave Alexa Fluor 647 donkey anti-chicken IgG (HþL)
Normal donkey serum 5% w/v Sigma-Aldrich (D9663)
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FIGURE 3. Complement deposition in the choroid plexus (CP). Complement components (green) are shown in relation to the
CP epithelium (transthyretin in purple), basement membrane (collagen IV in red), cell nuclei (DAPI in blue), and stromal
concretions (asterisks). (A) C1q is seen in the CP stroma, a concretion, the cytoplasm of some epithelial cells, and some nearby
ependymal cells (green arrows, shown at higher magnification in inset). (B) C3d is present in the stroma and in the superficial
aspects of a concretion; the overlying subepithelial basement membrane is discontinuous and focally incorporated into the
concretion. (C) C9 is evident in a concretion and is deposited adjacent to the basement membrane, with which it directly
colocalizes (embeds within) only rarely (yellow). (D) High magnification of the upper left of panel C, showing C9 deposited
adjacent to, but not directly colocalizing with (embedded within), subepithelial basement membrane; stippled pattern of C9
deposition shown on the left. (E) High magnification of the lower right of panel C, showing stippled C9 deposition adjacent to
subepithelial basement membrane but only focally directly colocalizing with (embedded within) it (yellow). (F) C9 is present in a
concretion and is deposited adjacent to the overlying subepithelial basement membrane, which is both focally interrupted
(between the white arrows) and thickened in this region. (G) Two concretions show deposition of C9neo, with interruption
(right concretion) and thickening (right and left concretions) of the overlying subepithelial basement membrane, which is also
incorporated into their deeper structures. (H) A prominent C9neo deposition in the superficial aspect of a concretion and
adjacent to a discontinuous subepithelial basement membrane, with which there is focal direct colocalization (yellow).
(I) Staining for only C9neo (counterstained for nuclei) shows delicate subepithelial basement membrane-associated deposits.
Scale bars: white¼20 mm; red¼10 mm.
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ous as staining with the antibody to the C9 component and the
earlier components of the cascade; by confocal microscopy,
this manifested as minute discrete punctate deposits adjacent
to or in the BM (Fig. 3I). Vasculature staining was occasion-
ally seen but epithelial and stromal staining was less frequent.
Complement components were detected in concretions
with a significantly higher frequency than in epithelial cells
(p<0 .0001, Fig. 5). Overall, the complement components that
were frequently deposited in the CP were more likely found
in concretions than immunoglobulins; this was significant
(Fig. 5). The close association of complement components
with BM was confirmed by their spatial relationship to colla-
gen IV (Fig. 3B–F, H, I), but direct colocalization indicating
complement embedment in BMwas infrequent (Fig. 3E, H).
Localization of Immunoglobulins
Generally, staining for immunoglobulin isotypes showed
a great deal of variability, ranging from negative to focal posi-
tivity. Because they circulate in the serum, they also, not unex-
pectedly, showed focal positivity in the stroma (Fig. 4A–C;
Table 4); BM associated with (Fig. 4A) and unassociated with
(Fig. 4B, C) concretions (Table 4). CP rarely showed staining
for IgD or IgE (Table 4).
In contrast to complement, IgA and IgG were only occa-
sionally positive in concretions but were more frequently evi-
dent in epithelial cells (p< 0.0001) (Fig. 4A, B; Table 4). IgM
had no particular preference for either of these locales (Fig.
4C, D; Table 4). When each of the tested molecules was com-
pared to one another, epithelial cell staining was seen for IgA
and IgG more often than for IgM, C3d, C9, and C9neo; these
differences were significant (Fig. 5). Epithelial cells more su-
perficially in the CP and closer to C1q-positive or immuno-
globulin-positive ependymal cells often tended to be positive
for C1q or immunoglobulins, whereas deeper cells were nega-
tive (Figs. 3A, 4B).
No Pattern of Complement or Immunoglobulin
Is Specific for MS
We were initially struck by a diffuse stromal and BM
IgA or a diffuse stippled BM C9 deposition in cases of MS.
Therefore, we expanded the study to include more cases
stained for IgA, C9, and C9neo and found these patterns still
tended to be seen more often in MS than in other conditions,
but this was not a statistically significant difference (Tables 3,
4). A reverse trend was noted for C1q in epithelial cells. These
patterns were seen in MS cases irrespective of the presence of
actively demyelinating or silent plaques.
DISCUSSION
Complement Preferentially Localizes in CP
Concretions
Our results show the consistent deposition of comple-
ment components (except C4d, which was only rarely evident
in the CP) in the stromal concretions of the CP. Complement
components that were frequently deposited in the CP were sig-
nificantly more commonly found in concretions than in epithe-
lial cells (p< 0.005). This suggests that the concretion is an
important depot for complement deposition and offers an im-
portant function for these previously unexplored structures.
Complement frequently had a spatial relationship to collagen
IV (Fig. 3C, E), but its direct colocalization with this BM
marker was infrequent (Fig. 3C), indicating that complement
may be adherent to the BM without necessarily impregnating
it. The existence of collagen IV–positive material within con-
cretions suggests that BM material was incorporated within
them. Moreover, BM absence, duplication, or thickenings at
the epithelial pole of the concretion are also consistent with
active BM involvement in the function of this structure. The
findings are somewhat analogous to the deposition of comple-
ment in the glomerular subepithelial space or outer aspect of
TABLE 3. Percentage of Cases Positive for Complement
C0 Percent Positive; p Value EP BM BMs BMc C S V Any
C1q Percent positive MS 8 46 0 62 77 100 38 100
Percent positive non-MS 66 51 6 69 89 80 31 97
p value 0.007 > 0.999 > 0.999 0.74 0.37 0.17 0.74 > 0.999
C3d Percent positive MS 0 54 0 69 100 92 38 100
Percent positive non-MS 3 49 6 91 100 94 3 100
p value > 0.999 > 0.999 > 0.999 0.08 > 0.999 > 0.999 0.004 > 0.999
C4d Percent positive MS 0 15 0 23 8 0 0 31
Percent positive non-MS 6 31 0 14 14 0 0 40
p value > 0.999 > 0.999 > 0.999 0.66 > 0.999 > 0.999 > 0.999 0.74
C9 Percent positive MS 21 4 71 38 96 13 67 100
Percent positive non-MS 7 3 42 31 98 10 83 98
p value 0.112 > 0.999 0.03 0.61 0.50 0.71 0.14 > 0.999
C9 neo Percent positive MS 13 17 4 4 67 8 21 75
Percent positive non-MS 7 16 0 3 79 14 21 81
p value 0.41 > 0.999 0.29 > 0.999 0.26 0.72 > 0.999 0.56
Any, staining of any of the following components of the choroid plexus; BM, epithelial basement membrane staining; BMc, staining of epithelial basement membrane overlying
concretion; BMs, stippled staining of epithelial basement membrane; C, staining of concretion; EP, epithelial cell staining; S, staining of stroma; V, staining of stromal vasculature.
p< 0.0007 after Bonferroni correction.
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FIGURE 4. Immunoglobulins in the choroid plexus. Confocal micrographs showing immunoglobulins in green, basement
membrane (collagen IV) in red, epithelial cells (transthyretin) in purple, and cell nuclei (DAPI) in blue. (A) IgA (green) is seen in
the stroma, focally colocalizing in the subepithelial basement membrane (yellow), and in the cytoplasm of epithelial cells. (B)
IgG (green) is evident in the stroma and in some epithelial cells near IgG-positive ependymal cells (green arrows). (C) IgM
(green) is focally evident in the stroma and in some epithelial cells. (D) IgM deposition in a concretion (asterisk), which is
associated with a defect in the overlying subepithelial basement membrane. There is focal basement membrane thickening
within which there is colocalization with IgM (yellow). Some basement membrane material is also seen within the concretion.
Scale bars: green¼10 mm; white¼20 mm.
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the BM in membranous glomerulonephritis and the subse-
quent reaction of the BM in that disorder (66). There is also a
striking similarity to complement localization in the choroid
(which could be considered to be the equivalent of CP stroma)
and Bruch’s membrane (possibly the retinal equivalent of the
CP epithelial BM) (67). Furthermore, there is also comple-
ment deposition in drusen (68), which may be analogous to
the CP concretions described here. In the retina, these findings
have been implicated in the pathogenesis of macular degenera-
tion (69). However, in the CP, these phenomena are presum-
ably not pathogenic because they are exceedingly frequent
and evident even in nonimmune noninflammatory conditions.
It is, however, certainly possible that their progression is asso-
ciated with aging or age-related degeneration of the CP.
FIGURE 5. Choroid plexus concretion and epithelial cell (EP) staining. Significant differences are highlighted in green. Any
statistically significant comparisons for C4d, IgD, and IgE are attributable to the rarity of staining of these compared with the
other complement components and immunoglobulins. (A) Concretion staining was observed more often than EP staining for
C1q, C3d, C9, and C9neo. The reverse was true for IgA and IgG. There was no significant difference in the frequency between
concretion and EP staining for IgM. (B) There were significant differences in staining frequencies of concretions (more frequent,
see Tables 3 and 4) for C1q, C3d, C9, and C9neo than for IgA, IgG, and IgM. (C) There were significant differences in staining
frequency of epithelial cells for IgG and IgA (more frequent, see Tables 3 and 4) than for IgM C3d, C9, and C9 neo. Two-tailed
Fisher exact test, Bonferroni correction for multiple comparisons (SPSS Statistics 17.0).
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We hypothesize that complement within the stroma that
is derived from either the serum or the CSF is initially attracted
to and adherent to the BM, and the latter, with the attached
complement, is internalized within the concretion (Fig. 1),
which over time undergoes dystrophic calcification. C9neo, in-
dicating the complement cascade had been activated to com-
pletion resulting in the terminal MAC, was demonstrated in the
BM and concretions. Since C9 neoantigens are expressed both
in the MAC and in the soluble terminal complex, C9neo stain-
ing is firm evidence of activation of complement to completion
and means that cells in the vicinity will have been exposed to
the MAC. It is suggested that the deposition of this complex
within the BM and subsequently in the concretion would be a
means of preventing it from causing damage to CNS cells. It is
possible that many of the earlier components of the comple-
ment cascade detected in various compartments of the CP, in-
cluding the concretion, represent individual components or
parts of complexes that have failed to activate later components
to complete the cascade. Another and even more intriguing ex-
planation is that the aggregation of the components of comple-
ment is occurring in situ in the CP, the immunohistochemistry
demonstrating their generation at various stages. In this inter-
pretation, the concretions may be regarded as markers of previ-
ous complement-mediated destruction in the CP. In either sce-
nario, the data are consistent with complement being trapped
in the BM and the concretion.
Immunoglobulins Preferentially Localize in CP
Epithelium
In contrast to complement, IgA and IgG were only occa-
sionally positive in concretions but were more frequently evi-
dent in epithelial cells (p< 0.005). IgM, the immunoglobulin
produced earlier than IgA and IgG in the adaptive immune re-
sponse, appears to have no particular preference for either of
these locales. When each of the tested molecules were com-
pared to one another, epithelial cell staining was seen with
IgA and IgG significantly more often than IgM, C1q, C3d, C9,
and C9neo. Staining frequently was seen only in scattered epi-
thelial cells, rather than in a diffuse fashion throughout the epi-
thelium. Epithelial cells that were more superficially located
in the CP and closer to C1q-positive or immunoglobulin-
positive ependymal cells often tended to be positive for C1q
or immunoglobulins, whereas deeper cells were negative, sug-
gesting that C1q and immunoglobulin were being actively re-
moved from the ventricular CSF. However, directionality can-
not be stated with certainty based on this morphological data
alone. Nevertheless, substantiating this interpretation is the
finding that, in experimental animals, transport of IgG across
the CP is largely an efflux system (CSF to blood) rather than
in the other direction (3, 70). Because serum molecules may
diffuse in small quantities through the blood–brain and
blood–CSF barriers (8, 71), the findings suggest that the CP
epithelial cells may serve to recycle these leaked proteins to
the circulation by transporting them from the CSF into the
CP serum-rich stroma. The finding of IgG positivity in CP
epithelial cells is not new, having been reported in the hu-
man neonate (72, 73). Our results indicate that this is also an
adult phenomenon and that this location is highly character-
istic of immunoglobulins.
Despite the fenestration of vessels in the CP stroma, the
finding of immunoglobulins in the stroma was not consistent.
Interestingly, in a study of EAE, IgG was detected in the CP
stroma in animals given complete Freund’s adjuvant, with or
without the immunogen, but not in controls, suggesting that
systemic inflammatory signals may be necessary to produce
increased permeability above baseline in these vessels to allow
extravasation of the immunoglobulin (74). By inference, this
may indicate that stromal immunoglobulin may be a reflection
of systemic inflammation. In this regard, we initially noted a
diffuse stromal and BM IgA or a diffuse stippled BMC9 depo-
sition in MS cases. In light of this finding, we expanded the
TABLE 4. Percentage of Cases Positive for Immunoglobulins
Ig Percent Positive; p Value EP BM BMs BMc C S V Any
IgA Percent positive MS 79 79 0 46 42 75 4 96
Percent positive non-MS 61 54 0 29 17 32 0 88
p value 0.13 0.05 > 0.999 0.20 0.02 0.001 0.29 0.43
IgG Percent positive MS 69 62 0 38 31 69 0 77
Percent positive non-MS 69 46 0 49 23 40 0 77
p value > 0.999 0.52 > 0.999 0.75 0.71 0.11 > 0.999 > 0.999
IgM Percent positive MS 8 85 0 31 15 85 0 92
Percent positive non-MS 26 46 0 31 43 60 0 80
p value 0.25 0.022 > 0.999 > 0.999 0.099 0.17 >.999 0.42
IgD Percent positive MS 0 0 0 0 0 0 0 0
Percent positive non-MS 3 0 0 0 0 3 0 3
p value > 0.999 > 0.999 > 0.999 > 0.999 > 0.999 > 0.999 > 0.999 > 0.999
IgE Percent positive MS 0 0 0 0 0 0 0 0
Percent positive non-MS 9 6 0 0 0 0 0 12
p value 0.55 > 0.999 > 0.999 > 0.999 > 0.999 > 0.999 > 0.999 0.56
Any, staining of any of the following components of the choroid plexus; BM, epithelial basement membrane staining; BMc, staining of epithelial basement membrane overlying
concretion; BMs, stippled staining of epithelial basement membrane; C, staining of concretion; EP, epithelial cell staining; S, staining of stroma; V, staining of stromal vasculature.
p< 0.0007 after Bonferroni correction.
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study to include more MS and non-MS cases stained for IgA
and C9 and found these patterns tended to be seen in MS more
than other conditions, but this was not a significant difference.
It is possible that both these trends may be explained by sys-
temic inflammation, for example pulmonary or urinary in-
fections, to which patients with advanced MS are particularly
susceptible. Nevertheless, the trend raises the possibility that
these phenomena in the CP may be relevant to the immunopa-
thogenesis of some cases of MS. This may also be true of the
trend toward decreased C1q staining in epithelial cells in MS.
These trends might have been clarified if we had clinical infor-
mation about the MS cases, but unfortunately, these were often
unavailable to us.
The CP as a Possible Systemic Immunologic
Filter
This study further defines the role of the CP in hu-
moral and innate immunity. Detoxification and complement
and immune complex removal have largely been attributed
to organs such as the liver and spleen (75, 76). Our results
would suggest that the CP, by utilizing trapping mechanisms
employed by its epithelial cells, BM, and concretions, may
serve a similar role for the brain, protecting it from immune-
mediated and other potentially toxic systemic threats. It is
also possible that similar functions may be ascribed to other
CNS concretion-like structures, such as corpora amylacea
(77) and psammoma bodies for the compaction or disposal
of degraded endogenous molecules and toxic compounds
that have already made their way to the CNS parenchyma or
leptomeninges, respectively. We hope that this study, which
represents static snapshots in time imaged by immunofluo-
rescence, will spawn immunological, physiological, and
molecular approaches to test and refine further the hypothe-
ses generated by our data. Furthermore, the possibility that
these CP clearance functions are also systemically important
for the entire organism, not just the brain in which it is stra-
tegically poised, is also an important consideration worthy
of further exploration.
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